Intellia Therapeutics, Inc.
NTLA
$9.20
-$0.40-4.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.42% | 2.47% | -11.04% | -18.83% | -4.18% |
| Total Depreciation and Amortization | -0.56% | 4.06% | 13.89% | 19.77% | 22.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.01% | 16.60% | 18.86% | 56.42% | -51.16% |
| Change in Net Operating Assets | -97.75% | -34.41% | 172.61% | 695.46% | 19.43% |
| Cash from Operations | -23.43% | 8.45% | 16.32% | 35.58% | -10.37% |
| Capital Expenditure | 70.67% | 35.46% | 70.48% | 76.47% | 34.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,030.76% | 221.43% | -107.67% | 23.35% | 107.10% |
| Cash from Investing | 1,498.51% | 229.93% | -109.70% | 29.96% | 104.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -97.82% | 330.28% | 1,539.35% | 2,601.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -97.82% | 330.28% | 1,539.35% | 2,601.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.30% | 15.70% | -272.58% | 66.38% | 76.12% |